# Fortress Biotech Inc. (FBIO)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $77M  
**Price:** $2.77 (-5.46%)

> Fortress Biotech Inc. operates as a biopharmaceutical company involved in the development and commercialization of novel pharmaceutical and biotechnology products. Its primary function is to nurture and advance a diverse portfolio of potential new treatments for rare diseases, cancer, and other serious health conditions. A distinctive feature of Fortress Biotech is its innovative partnership model; it acquires, develops, and commercializes these therapies through multiple subsidiary companies and licensing agreements. This structure allows for specialized focus and flexibility in progressing early-stage drug candidates. Fortress Biotech significantly impacts the healthcare sector, particularly in areas of unmet medical needs where it seeks to bring breakthrough therapies to market. By creating a platform for research and development across its subsidiaries, the company plays a crucial role in fostering advancements in medical treatments and addressing critical gaps within pharmaceutical innovation and patient care.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $63M | $42M | -$70M | $7M | $-0.07 |
| 2024 | $58M | $37M | -$110M | -$46M | $-2.69 |
| 2023 | $85M | $62M | -$142M | -$61M | $-8.47 |
| 2022 | $76M | $45M | -$204M | -$87M | $-15.97 |
| 2021 | $69M | $37M | -$189M | -$65M | $-0.79 |
| 2020 | $46M | $31M | -$94M | -$47M | — |
| 2019 | $37M | $26M | -$111M | -$40M | — |
| 2018 | $27M | $21M | -$120M | -$84M | — |
| 2017 | $17M | $14M | -$90M | -$67M | — |
| 2016 | $16M | $16M | -$66M | -$55M | — |
| 2015 | $863,000 | $863,000 | -$51M | -$48M | — |
| 2014 | — | — | -$21M | -$20M | — |
| 2013 | — | — | -$36M | -$37M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $186M | $123M | $50M | $79M | $54M |
| 2024 | $144M | $146M | $23M | $57M | $58M |
| 2023 | $168M | $166M | $23M | $81M | $61M |
| 2022 | $294M | $244M | $42M | $178M | $92M |
| 2021 | $397M | $171M | $109M | $306M | $43M |
| 2020 | $333M | $136M | $100M | $233M | $52M |
| 2019 | $226M | $154M | $26M | $137M | $85M |
| 2018 | $141M | $121M | $2M | $66M | $84M |
| 2017 | $246M | $125M | $53M | $95M | $68M |
| 2016 | $171M | $88M | $38M | $105M | $30M |
| 2015 | $119M | $34M | $57M | $98M | $24M |
| 2014 | $89M | $19M | $71M | $50M | $14M |
| 2013 | $101M | $19M | $81M | $100M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$66M | — | — |
| 2024 | -$80M | — | -$80M |
| 2023 | -$128M | $63,000 | -$128M |
| 2022 | -$179M | $3M | -$182M |
| 2021 | -$117M | $5M | -$121M |
| 2020 | -$84M | $2M | -$86M |
| 2019 | -$95M | $2M | -$97M |
| 2018 | -$99M | $7M | -$106M |
| 2017 | -$81M | $648,000 | -$82M |
| 2016 | -$46M | $6M | -$52M |
| 2015 | -$20M | $283,000 | -$21M |
| 2013 | -$30M | $40,000 | -$30M |
| 2012 | -$23M | $54,000 | -$23M |
| 2011 | -$11M | — | -$11M |
| 2010 | -$6M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/FBIO)